![]() | ![]() |
Formats:
|
||||||||||||||||||||
Copyright Suárez, van Dyk. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Endothelial Cells Support Persistent Gammaherpesvirus 68 Infection 1Department of Microbiology and Program in Molecular Biology, University of Colorado Denver School of Medicine, Aurora, Colorado, United States of America 2Department of Immunology, University of Colorado Denver School of Medicine, Aurora, Colorado, United States of America Jae U. Jung, Editor University of Southern California School of Medicine, United States of America * E-mail: Linda.VanDyk/at/uchsc.edu Conceived and designed the experiments: ALS LFvD. Performed the experiments: ALS. Analyzed the data: ALS LFvD. Contributed reagents/materials/analysis tools: ALS LFvD. Wrote the paper: ALS LFvD. Received December 3, 2007; Accepted August 12, 2008. This article has been cited by other articles in PMC.Abstract A variety of human diseases are associated with gammaherpesviruses, including neoplasms of lymphocytes (e.g. Burkitt's lymphoma) and endothelial cells (e.g. Kaposi's sarcoma). Gammaherpesvirus infections usually result in either a productive lytic infection, characterized by expression of all viral genes and rapid cell lysis, or latent infection, characterized by limited viral gene expression and no cell lysis. Here, we report characterization of endothelial cell infection with murine gammaherpesvirus 68 (γHV68), a virus phylogenetically related and biologically similar to the human gammaherpesviruses. Endothelial cells supported γHV68 replication in vitro, but were unique in that a significant proportion of the cells escaped lysis, proliferated, and remained viable in culture for an extended time. Upon infection, endothelial cells became non-adherent and altered in size, complexity, and cell-surface protein expression. These cells were uniformly infected and expressed the lytic transcription program based on detection of abundant viral gene transcripts, GFP fluorescence from the viral genome, and viral surface protein expression. Additionally, endothelial cells continued to produce new infectious virions as late as 30 days post-infection. The outcome of this long-term infection was promoted by the γHV68 v-cyclin, because in the absence of the v-cyclin, viability was significantly reduced following infection. Importantly, infected primary endothelial cells also demonstrated increased viability relative to infected primary fibroblasts, and this increased viability was dependent on the v-cyclin. Finally, we provide evidence for infection of endothelial cells in vivo in immune-deficient mice. The extended viability and virus production of infected endothelial cells indicated that endothelial cells provided a source of prolonged virus production and identify a cell-type specific adaptation of gammaherpesvirus replication. While infected endothelial cells would likely be cleared in a healthy individual, persistently infected endothelial cells could provide a source of continued virus replication in immune-compromised individuals, a context in which gammaherpesvirus-associated pathology frequently occurs. Author Summary Various human diseases are associated with gammaherpesvirus infections, including neoplasms of lymphocytes (e.g. Burkitt's lymphoma) and endothelial cells (e.g. Kaposi's sarcoma). Gammaherpesvirus infection of cells usually results in either productive infection that is characterized by new virus production and rapid destruction of the host cell, or latent infection that is characterized by long-term carriage of viral DNA in intact cells that do not produce virus. Here, we characterize endothelial cell infection using a small animal model of gammaherpesvirus infection and disease. While infection of endothelial cells resulted in virus production as most cells do, infection of this cell type was unique in that cells remained intact and continued to proliferate. These intact, infected endothelial cells were significantly altered in appearance and gene expression compared to uninfected cells, changes predicted to impact endothelial cell growth and function. Endothelial cells were unique in their ability to support this type of persistent infection. These data demonstrate an additional mechanism, beyond latency, by which gammaherpesviruses may achieve long-term propagation, particularly in conditions of immune suppression. Our results suggest persistently infected cells as a therapeutic target for prevention/treatment of chronic disease, and may provide a mouse model for future testing. Introduction Endothelial cells create a physical barrier on the luminal surface of blood and lymphatic vessels. This barrier must be traversed by blood-borne pathogens and immune cells trafficking between tissues and the bloodstream. Many herpesviruses require systemic spread for persistence within a host, and therefore must cross such an endothelial cell barrier. To date, herpesviruses have been implicated as potential initiators of arterial injury, endothelial dysfunction, and local inflammation, possibly contributing to the pathogenesis of atherosclerosis [1]–[4]. Human cytomegalovirus (HCMV), a betaherpesvirus, infects endothelial cells in vivo. Studies have shown that infected endothelial cells play a role in HCMV dissemination and pathogenesis [5]. Endothelial cells exhibit regional specialization in gene expression and morphology depending on the local physiologic demands of their respective organs and tissues [6]. In light of this diversity, it is not surprising that endothelial cells from different tissues differ in their susceptibility to HCMV infection [7]. Kaposi's sarcoma-associated herpesvirus (KSHV), a human gammaherpesvirus, also infects endothelial cells in vivo. More importantly, KSHV is the causative agent of the endothelial cell neoplasm, Kaposi's sarcoma (KS). The murine gammaherpesvirus, γHV68, has been detected in aortic endothelium after infection of apoE deficient mice, as well as on the luminal surface of explanted aortas infected in vitro [8]. While a relationship between gammaherpesviruses and endothelial cells has been noted, the role of endothelial cells in chronic gammaherpesvirus infection and pathogenesis is ill-defined. Gammaherpesviruses are a lymphotropic family of viruses associated with a broad spectrum of malignancies and lymphoproliferative diseases. These oncogenic viruses persist for the life of the host by establishing and maintaining a latent infection. Because gammaherpesviruses are extremely host-specific, studying the human viruses Epstein-Barr virus (EBV) and KSHV in non-human systems does not mimic natural infection. γHV68 is a natural pathogen of wild murid rodents and therefore provides a valuable small animal model of gammaherpesvirus infection [9]–[13]. This virus has important biological and genetic similarities to the human gammaherpesviruses, and results in a variety of pathologies in defined mouse models. Primary γHV68 infection is characterized by virus replication in lung epithelial cells, and the establishment of latency in B cells, dendritic cells, and macrophages [12]–[16]. Persistent γHV68 infection also occurs in lung epithelial cells [17]. The role of endothelial cells in γHV68 infection has not been explored to date. At the cellular level, gammaherpesvirus infection encompasses two broadly defined outcomes: productive, lytic replication and non-productive, latent infection. During lytic replication, viral DNA is amplified and host cell machinery is utilized for the production of viral progeny. Viral genes are actively transcribed and translated, contributing to new virus production. Ultimately, the cell is lysed and infectious virus released. In light of the fact that this process occurs quickly (24 to 48 hours in vitro) our understanding of virus-host interactions during primary infection is quite limited. During latency, viral DNA is not amplified, but instead is maintained as a nuclear episome in latently infected cells, and little viral gene transcription occurs. Latently infected cells remain intact and do not produce new infectious virus. Furthermore, it is thought that these long-lived latent cells may serve as the major mechanism by which gammaherpesviruses promote life-long infection of their hosts. Here we characterize γHV68 infection of endothelial cells. To date, in vitro infection of most cells with γHV68 supports significant viral replication and results in complete cell lysis (data not shown, van Dyk). We have infected both primary endothelial cells and endothelial cell lines and demonstrated that they produce comparable amounts of virus as fibroblasts. However, whereas fibroblasts were mostly lysed by 36–48 hours post-infection, a significant percentage of infected endothelial cells remained intact. Analysis of endothelial cell lines revealed that these intact cells 1) were actively infected and undergoing the lytic transcriptional program, 2) continued to proliferate for a prolonged time after infection, 3) were altered in morphology and cell-surface protein expression, compared to uninfected endothelial cells, and 4) continued to release infectious virions as far as 30 days post-infection. In the absence of the γHV68 viral cyclin, endothelial cell viability was significantly decreased after infection, indicating that an active viral process was responsible for promoting the outcome of infection in endothelial cells. Of major significance, we also provided evidence of endothelial cell infection in primary cells and in vivo in immune-deficient mice. These data demonstrated that endothelial cells supported persistent, productive gammaherpesvirus infection, an outcome not previously reported for γHV68 or other gammaherpesviruses. Together, these data indicated the potential of the endothelial cell as a critical cell type in γHV68 pathogenesis, and open a new avenue of research into herpesvirus manipulation of endothelial cell biology. Results Endothelial cells supported γHV68 replication Endothelial cells are heterogeneous in nature, express unique surface antigens, and differ in their susceptibility and response to infection by various pathogens [6]. In light of this diversity, we investigated endothelial cell lines from various anatomic locations, and from BALB/c and C57BL/6 mice, for their ability to support γHV68 replication. We analyzed the outcome of γHV68 infection in endothelial cell lines from lung (CD3), brain capillary (MB114), and lymph node (SVEC) by single-step and multi-step growth assays. Single step growth proceeded with kinetics similar to previously published infection of the fibroblast cell line, NIH 3T12 cells [18] in each of the three endothelial cell lines analyzed (Fig. 1A
Using a GFP-labeled virus, we next sought to determine if the percentage of infected endothelial cells was comparable to percentage of infected fibroblasts. Following infection of MB114 endothelial cells and 3T12 fibroblasts, cells were analyzed for expression of GFP from the γHV68 genome by flow cytometry. At 24 and 48 hours post-infection the majority of endothelial cells and fibroblasts expressed GFP (Fig. 1B A population of endothelial cells remained intact following γHV68 infection and uniformly expressed lytic antigens Uninfected endothelial cells and fibroblasts grew as adherent monolayers (Fig. 2A
Next we determined the status of virus replication in the viable and non-adherent cells. Cells collected at six days post-infection were analyzed by flow cytometry for expression of the γHV68 glycoprotein, gp150, which is expressed during the lytic transcription program on the surface of infected cells [19]. Cell viability was also determined using propidium iodide (PI), a cell impermeant dye that is excluded from intact cell membranes. In these experiments we also included the S11E cell line, a mouse B cell lymphoma line which harbors latent γHV68, and therefore is negative for gp150 surface expression [20]. The majority of MB114 endothelial cells and 3T12 fibroblasts were positive for surface gp150 expression (Fig. 2C At 12 days post-infection we determined the viability of cells collected and cultured at six days post-infection. PI staining of S11 cells, after six days in culture, revealed that 51.7% (±2.5 SEM) of cells were PI negative and thus viable. PI staining of post-infection fibroblasts, treated in parallel with infected endothelial cells, revealed that only 14.5% (±1.5 SEM) of the cells harvested remained intact. In contrast, PI staining of post-infection endothelial cells revealed that 92.5% (±0.3 SEM) of the cells harvested were intact and viable (Fig. 2D
Intact endothelial cells were productively infected and underwent a continued lytic program The observed viability of endothelial cells after γHV68 infection could be the result of escape from infection or latent infection of these cells. To determine the infection status of the intact endothelial cells, we performed RT-PCR analysis of viral gene transcripts. The γHV68 M2 gene transcript is synthesized during both lytic and latent infection, as are the polymerase III (pol III) transcripts encoded at the left end of the viral genome [21],[22]. Latently infected S11 cells contained both pol III-1 and M2 transcripts (Fig. 3A To determine whether the intact, infected endothelial cells were undergoing active viral replication, we analyzed infected cells for the expression of early and late lytic replication-associated M3 and gB. As predicted, 3T3 fibroblasts, which support lytic replication, expressed both M3 and gB (Fig. 3B To further test the status of viral replication in endothelial cells, we infected MB114 endothelial cells with GFP-γHV68 and collected the intact, non-adherent cells at six days post-infection. GFP expression is driven by the CMV immediate early promoter and has been demonstrated to be expressed only during lytic infection [29]. At the time of harvest, these cells uniformly expressed GFP (Fig. 3D Intact, infected endothelial cells released new infectious virus particles After establishing that the intact endothelial cells harvested at six days post-infection were indeed infected, we determined whether these cells produced mature virions. Transmission electron microscopy (TEM) of these cells revealed virions at various stages of maturation throughout the nucleus and cytoplasm of 100% of the 20 cells imaged at 12 days post-infection (Fig. 4A
The culture conditions we established for maintaining the non-adherent cells included centrifugation and resuspension in fresh media every six days (Fig. S1). To test the contribution of non-adherent cells to virus production, aliquots of the supernatants were collected for measurement of cell-free virus. A culture of latently infected S11 cells did not yield any detectable cell-free virus after six days in culture by plaque assay (Fig. 4B Intact endothelial cells undergo transient proliferation in culture after γHV68 infection After the initial observation that γHV68 infection of several endothelial cell lines from different anatomic locations resulted in a population of cells that escaped lysis, we focused our analysis on this outcome in MB114 endothelial cells. Beginning at the time of collection (day six post-infection), we counted intact, trypan blue excluding cells every three days. Infected MB114 cells remained viable for at least 30 days post-infection (Fig. 5A
During this course of infection, the number of intact cells in the culture increased from 7.08×105 (±0.16 SEM) to 8.51×106 (±0.28 SEM) during the first six days of culture, a ten-fold increase. A corresponding increase in the percentage of membrane viable cells also occurred during this time. Subsequent to day 12 post-infection, the total number of intact cells began to decrease, as did the overall viability of the culture (Fig. 5A To further examine the proliferation observed during the first six days of culture, we stained MB114 cells with carboxyfluoroscein (CFSE) prior to infection. CFSE is a fluorescent molecule used to measure cell proliferation, in that each time a cell divides, the two daughter cells contain half the CFSE of the parent cell. S11 cells demonstrated a drop in CFSE signal intensity after six days in culture, consistent with cell division. At the time of harvest (day six post-infection), MB114 cells also demonstrated a drop in CFSE signal intensity consistent with multiple cell divisions (Fig. 5B Note that by 30 days post-infection, however, the viability of the culture was quite low in comparison to earlier time points (Fig. 5A Intact endothelial cells were altered in size, shape, and surface marker expression after γHV68 infection To investigate the morphologic differences between uninfected endothelial cells and the endothelial cells harvested at six days post-infection, we quantified cell size and internal granularity by flow cytometric determination of forward versus side scatter. Uninfected MB114 cells exhibited a broad range of light scatter, indicative of a cell population diverse in size and internal granularity. In contrast, infected cells were very uniform in forward and side scatter (Fig. 6A
To further investigate the differences between uninfected endothelial cells and the intact cells harvested six days after infection, we compared the expression of cell-surface proteins on these two cell populations by flow cytometry. Because the cells harvested at six days post-infection persisted in culture as non-adherent cells, we chose to investigate surface expression of the adhesion markers intercellular adhesion molecule-1 (ICAM-1, CD54) and vascular cell adhesion molecule-1 (VCAM-1, CD106). Additionally, we analyzed cells for surface expression of Thy1, a cell surface protein which is upregulated on the surface of activated endothelial cells and functions in cell-cell interactions [30]–[32]. Uninfected MB114 cells expressed ICAM-1, VCAM-1, and Thy1 (Fig. 6B In the absence of the viral cyclin, endothelial cell viability after γHV68 infection is reduced We demonstrated that γHV68 infection of endothelial cells resulted in a population of intact cells which persisted in culture as non-adherent cells and continued to produce new virus. Our analysis of endothelial cell infection in the presence of PAA indicated that this outcome is influenced by viral DNA replication and/or late gene synthesis (Fig. 2B
To determine the role of the v-cyclin in endothelial cell infection, we infected MB114 cells with either wildtype γHV68 or a v-cyclin deficient γHV68 (v-cyclin.STOP γHV68) [18]. Cells were harvested at six days post-infection and cultured as described previously. As per previously published reports in fibroblasts, we determined that the v-cyclin was dispensable for γHV68 growth in endothelial cell lines by multi-step growth assays (data not shown). Cultures of MB114 cells infected with wildtype virus were 48.5% (±0.61 SEM) viable at day six, 79.4% (±0.36 SEM) viable at day nine, 91.3% (±0.26 SEM) at day 12, and 62.2 % (±1.33 SEM) at day 15 post-infection. In contrast, cultures of MB114 cells infected with v-cyclin.STOP γHV68 were 15.1% (±2.093 SEM) viable at day 6, 8.4% (±1.767 SEM) viable at day 9, 18.4% (±5.304 SEM) viable at day 12, and 27.7% (±5.817 SEM) viable at day 15 post-infection. Therefore, in the absence of the v-cyclin, endothelial cell viability was significantly impaired after γHV68 infection. Because viability of MB114 cells after infection was impaired in the absence of the v-cyclin, we next determined the effect of this viral gene on persistent viral replication in viable endothelial cells. Cell free supernatants from infected MB114 cells were titered by plaque assay (Fig. 7C Primary endothelial cells were infected in vivo, and ex vivo demonstrated prolonged viability while supporting γHV68 growth Given that immortalized endothelial cell lines are inherently different from endothelial cells in vivo, we next determined the outcome of γHV68 infection in primary endothelial cells. Primary endothelial cells were isolated from C57/BL6 mouse lungs and characterized as per previously published methods (Fig. S4). First, we determined if primary lung endothelial cells could support growth of wildtype γHV68 by multi-step growth assay (Fig. 8A
Second, we analyzed the percent of cells that remained viable after γHV68 infection at a low MOI. Immediately following removal of the viral inoculum (t = 0), mouse embryonic fibroblasts (MEFs) and primary lung endothelial cells did not differ significantly in viability (p>0.05) (Fig. 8BLastly, we examined lung endothelial cells following acute γHV68 infection in vivo. Our in vitro studies revealed that viable, infected endothelial cells were not latently infected, but uniformly supported a lytic viral program (Fig. 2C To further demonstrate that these viral genome positive cells are actively infected, and to exclude the possibility of endocytic uptake of virus or abortive infection, we performed RT-PCR analysis on endothelial enriched and depleted lung cells (Fig. 8D Discussion Herpesviruses have been implicated as potential initiators of a variety of endothelial pathologies [1]–[4]. Given the intimate interactions observed between herpesviruses and endothelial cells, and the systemic spread of γHV68 during infection, we characterized the outcome of endothelial cell infection with γHV68, a small animal model for the human gammaherpesviruses. While γHV68 replicated comparably in endothelial cells and fibroblasts up to 36 hours post-infection, infected cultures of endothelial cells had a high percentage of viable, non-adherent cells that remained following infection. Of significance, these viable, non-adherent cells had not simply escaped infection, but instead were actively infected, as determined by the presence of multiple markers of the lytic replication program. While the absolute number of viable, infected endothelial cells varied among different cell lines and primary cells, the prolonged viability of endothelial cells in comparison to fibroblasts was remarkably consistent in endothelial cell lines from distinct anatomic locations, as well as in primary endothelial cells. Furthermore, optimal survival of both endothelial cell lines and primary endothelial cells was dependent on the presence of the γHV68 v-cyclin, indicating that this outcome was a process actively promoted by virus infection. This conserved outcome of endothelial cell infection is particularly striking given that endothelial cells display phenotypic heterogeneity in structure and function depending on anatomic location [33]–[35]. Based on the persistent infection observed in diverse endothelial cell lines, and heightened viability of primary endothelial cells following infection, we propose that γHV68 may have evolved machinery to specifically promote persistent infection in endothelial cells. Endothelial cells serve as a natural site of infection and possible viral reservoir of HCMV [36]–[40], suggesting a role for HCMV-infected endothelial cells in viral spread and persistence. Additionally, recent reports implicate circulating endothelial progenitor cells as potential reservoirs of KSHV and possible precursors of KS spindle cells [41],[42]. However, the specific mechanisms by which infected endothelial cells contribute to the pathogenesis of these human viruses remains unclear. Murine γHV68 pathogenesis involves dissemination from the lung to lymph nodes, spleen, and peritoneum [12],[15]. In light of this systemic spread, γHV68 likely encounters an endothelial cell barrier. The human gammaherpesvirus KSHV causes a serious endothelial cell malignancy, KS, which predominantly occurs in immune-compromised individuals (e.g. AIDS patients). KS tumors are comprised of distinctive spindle cells of endothelial origin and a variable inflammatory infiltrate [43]–[46]. KSHV is detected primarily in the endothelial component of the lesion, and though most of these cells harbor latent KSHV, a subset of them enter the lytic cycle [47],[48]. While there is precedent for a mixed infection type within KS tumors (i.e. both lytic and latent infection), the history of the lytically infected cells remains elusive, though recent reports point to circulating endothelial progenitor cells [41],[42]. In vitro, endothelial cell infection with KSHV is predominantly latent [43], [49]–[51]. However, when these cells are transferred into mice, they show evidence of lytic gene expression and virus production [52]. Because viral DNA replication and/or late gene synthesis were important for endothelial cell outcome of γHV68 infection (Fig. 2B While our initial analysis focused on the role of the v-cyclin, it is very likely that additional viral genes facilitate persistent endothelial cell infection. Lead candidates include the anti-apoptotic viral bcl-2 gene M11 and the viral GPCR (ORF 74), whose homologs in KSHV have been implicated in endothelial cell survival and transformation [56]–[59]. Additional candidates for optimal endothelial cell infection are the ribonucleotide reductase homologs, ORF 60 and 61 of γHV68. Although the role of these genes in γHV68 infection of endothelial cells is currently untested, the MCMV ribonucleotide reductase homolog is required for in vivo replication and pathogenesis of this endothelial cell-tropic virus [60]. One of the most noticeable alterations of the persistently infected endothelial cells described here is the extent of change in their cellular morphology and properties. Though we did not test the oncogenic potential of these cells, endothelial cells achieved anchorage-independent growth, a property frequently associated with oncogenic transformation. These cells also underwent significant changes in protein expression on the cell surface, with down-regulation of the cellular adhesion proteins ICAM-1 (CD54) and VCAM-1 (CD106). While there was decreased expression of ICAM-1 and VCAM-1, changes in cell surface expression were not global, since Thy1 expression remained positive on these cells (Fig. 6B While γHV68 may have evolved mechanisms that promote persistent infection of endothelial cells (e.g. the v-cyclin), it is also possible that endothelial cells have a cellular program that limits the cellular lysis typically observed during productive infection. This putative cellular adaptation may be particularly important in limiting destruction of blood vessel integrity during viral infection. A recent report of host cell response to γHV68 in three different cell types (fibroblasts, endothelial precursor cells and macrophages) identified 148 genes whose expression was altered in endothelial precursor cells, but not macrophages or fibroblasts [67]. Taken together with the unique endothelial cell outcome of γHV68 infection reported here, these data make a compelling argument for cell type specific responses to productive γHV68 infection. We have provided evidence for γHV68 infection of endothelial cells in vivo at early times post-infection. Interestingly, infected cells (including endothelial cells) were not abundant in acutely infected lung tissue, as little to no GFP was detected by flow cytometric analysis of unfractionated lung cells after infection with a GFP-marked virus (data not shown), but required sensitive PCR methods for detection. Our in vitro analysis demonstrated a change in surface phenotype of infected endothelial cells which could correspond to substrate detachment and release into circulation. This is an intriguing idea in light of published reports of circulating endothelial cells and progenitor endothelial cells in virus infection. Our in vitro studies implicated endothelial cells as a persistent source of virus production, however, the extent to which endothelial cells contribute to γHV68 persistence in vivo, and to what degree it might be influenced by host immune status, are important issues that remains to be addressed. While it is unlikely that an intact immune response would permit such long-term expression of viral antigens in vivo, we hypothesize that persistently infected endothelial cells could provide a significant source of continued virus replication in immune-compromised individuals (i.e. AIDS patients), a context in which gammaherpesvirus-associated pathology frequently occurs. Given the unusual properties of these viable and infected endothelial cells (e.g. anchorage-independent growth and altered cell surface protein expression), it will be important to critically address the potential role of endothelial cells as a reservoir for infection in vivo in both immune-competent and immune-deficient individuals. In conclusion, our data provide evidence for prolonged gammaherpesvirus infection in endothelial cells. This outcome appears to be the result of a specific interaction between γHV68 and endothelial cells, as it is promoted by a viral gene (the γHV68 v-cyclin) and, to date, is unique to endothelial cells. These data further refine the concept of gammaherpesvirus infection and demonstrate that a gammaherpesvirus can undergo robust productive replication in the context of prolonged host cell viability. Identification of intermediate outcomes of gammaherpesvirus infection, such as the one we have described here, has major implications for our understanding of the nature of gammaherpesvirus infection as it relates to specific cell types. Such a course of infection provides an additional mechanism, beyond latency, by which gammaherpesviruses can achieve long-term propagation. Materials and Methods Viruses and tissue culture Mouse fibroblast cell lines 3T3 (ATCC CRL-1658) and 3T12 (ATCC CCL-164) and mouse endothelial cell lines MB114 [68], SVEC4-10 (ATCC CRL-2181), and CD3 [69] were cultured in Dulbecco's Modified Eagle Media (DMEM) supplemented with 5% FBS (Hyclone, Logan, UT), 2 mM L-glutamine, 10 U/mL penicillin, and 10 µg/mL streptomycin sulfate. S11 [20] and S11E tumor cells [22] were cultured in RPMI 1640 medium (Gibco) supplemented with 10% FBS, 50 µM β-mercaptoethanol, 1 mM sodium pyruvate, 2 mM L-glutamine, 10 U/mL penicillin, and 10 µg/mL streptomycin sulfate (complete RPMI). Mouse embryonic fibroblasts were isolated from C57/BL6 mice as previously described [70] and cultured in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 10 U/mL penicillin, 10 µg/mL streptomycin sulfay7te, and 250 ng/mL fungizone. Isolation, characterization, and culture of primary endothelial cells from C57/BL6 mice was done according to previously published methods [71] and is described in Protocol S1, Text S1 and Figure S3A. γHV68 WUMS (ATCC VR-1465) and all recombinant viruses were grown and titered as previously described [72]. ΔK3TET− γHV68 (γHV68-GFP) containing a GFP cassette under the control of an immediate early CMV promoter was generated and characterized by Dr. Phillip Stevenson [73]. γHV68 containing a stop codon within ORF 72 (v-cyclin.STOP. γHV68) was previously described [18]. All infections were carried out at a multiplicity of infection (MOI) of 5 plaque forming units (PFU) per cell. Inoculum was removed after one hour of infection at 37°C, cell monolayers rinsed three times with sterile phosphate buffered saline (PBS), and complete media added. Intact and non-adherent cells were collected at six days post-infection, at which time cells and media were collected, counted to determine post-infection viability by trypan blue exclusion, and then centrifuged for 10 minutes at 208×g. Cell pellets were washed twice in sterile PBS and then resuspended in complete RPMI at a concentration of 5×105 viable cells/mL for continued culture. Cells were counted every three days of culture, and adjusted to a concentration of 5×105 viable cells/mL. Every six days of culture, cells were counted and centrifuged for 10 minutes at 208×g to remove cell-free γHV68 and cellular debris. Pellets were washed twice in sterile PBS and resuspended in RPMI at a concentration of 5×105 viable cells/mL. Culture scheme is depicted in supplement (Fig. S1). Viral titer by plaque assay To measure virus replication, infected samples were analyzed by plaque assay at various times post-infection. To measure cell-free virus titer from infected cultures, supernatants were collected every six days of culture and analyzed by plaque assay. Samples were thawed, serially diluted, and plated onto NIH 3T12 cells in 12 well plates in triplicate. Infection was performed at 37°C for one hour. Cells were overlaid with a 1 1 mix of DMEM and carboxymethylcellulose plus fungizone (final concentration 250 ng/mL). Plates were incubated for seven days at 37°C. On day seven, carboxymethylcellulose was removed, and plates were stained with 0.35% methylene blue in 70% methanol and rotated for 15–20 minutes, before rinsing with water and counting on a light box. All titers were determined in parallel with a laboratory standard.Flow cytometry For propidium iodine (PI) viability studies, cells were washed twice in PBS (five minutes, 1000×g), resuspended in a 0.5 µg/mL PI solution, and incubated for 15 minutes. Following incubation, cells were centrifuged (five minutes, 1000×g) and washed in a solution of PBS, 2% fetal calf serum, and 0.1% NaN3 (buffer A). Cells were fixed in 1% paraformaldehyde, and analyzed by flow cytometry. For two parameter viability analysis, cells were washed in 1X annexin V binding buffer (BD Bioscience, San Jose, CA), resuspended in 0.5 µg/mL PI and 5 µL annexin V-FITC (BD Bioscience), incubated for 15 minutes, washed in binding buffer, fixed in 1% paraformaldehyde, and analyzed by flow cytometry. For carboxyfluorescein (CFSE) proliferation studies, MB114 cells and Sll cells were washed twice in PBS (five minutes, 1000×g) and resuspended in a solution of PBS and 2% fetal calf serum (buffer B) at a concentration of 1×106 cells per mL. An equal volume of 4 µM CFSE in buffer B was added to the cell suspension (2 µM final concentration) and pipet mixed. After three minutes the labeling reaction was quenched with an equal volume of fetal calf serum for 30 seconds, and buffer B was added for a total volume of 50 mL. Cells were centrifuged (five minutes, 1000×g), resuspended in buffer B, and aliquots collected for day 0 analysis. Remaining, labeled cells were resuspended in complete media and cultured. Labeled MB114 cells were infected at an MOI = 5 PFU/cell. Infected cells were harvested as described at day six post-infection and analyzed by flow cytometry at six and 12 days post-infection. Stained and unstained S11 cells were analyzed at the same time as a positive control.For surface marker staining, cells were washed twice in buffer A (five minutes, 1000×g) and resuspended in primary antibody (1 200 in buffer A, 25% 24G2 [74]). The following primary antibodies were used: CD106-biotin (Rat, IgG2a κ, clone 429 (MVCAM.A)), CD54-FITC (Armenian hamster, IgG1 κ, clone 3E2), Thy1.2-APC (Rat, IgG2a κ, clone 53-2.1) (BD Bioscience), monoclonal mouse anti-γHV68 gp150 (mouse IgG2a, a kind gift from Dr. Phillip Stevenson) [75]. Cells were then incubated for 45 minutes at room temperature. Following incubation, cells were centrifuged twice in buffer A (five minutes, 1000×g), resuspended in either buffer A or secondary staining reagent in buffer A (1 500), and incubated for 20–30 minutes at room temperature. Secondary staining reagents were either streptavidin-APC (BD Bioscience) or anti-mouse IgG2a-FITC (Rat IgG1 κ, clone R19-15) (BD Bioscience). Cells were centrifuged twice in buffer A (five minutes, 1000×g) and analyzed by flow cytometry.For forward versus side scatter analysis, MB114 cells harvested at six days post-infection were analyzed. Uninfected MB114 cells were detached from flasks with 0.5 mM EDTA and analyzed in parallel with infected cells. In certain experiments, to determine the effect of viral DNA replication and/or late gene synthesis on forward and side scatter properties, MB114 cells were treated with 200 µg/mL phosphonoacetic acid (PAA) after one hour of infection. At six days post-infection, non-adherent cells were harvested and counted by trypan blue exclusion to determine the percent of cells infected that were viable and non-adherent at time of harvest. Cells which remained adherent to the flask were then detached with 0.5 mM EDTA, combined with the harvested non-adherent cells, and analyzed by flow cytometry for forward and side scatter properties. Effective block of late gene synthesis was confirmed by plaque assay titer of treated cells. Viral titer was reduced 96.2% after 24 hours and 99.9% after six days as compared to untreated cells. 10 micron control beads were run in parallel with each experiment (Beckman Coulter, Fullerton, CA). Western analysis Cells were collected and boiled in Laemmli buffer for 10 minutes. Total protein concentration of each cell extract was determined by Lowry assay (DC protein assay kit, Bio-Rad, Hercules, CA). 10–20 µg of total protein per extract was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Proteins were electrotransferred (ThermoFisher Scientific, Portsmouth, NH) to PVDF membranes (Millipore, Billerica, MA) and blocked in PBS with 0.05% Tween-20 and 5% nonfat milk for one hour at room temperature. Western blots for γHV68 protein expression were incubated with 10 µg/mL monoclonal mouse anti-γHV68 gB [76] (kind gift of Dr. Phillip Stevenson), monoclonal mouse anti-γHV68 M3 at 1 50, polyclonal rabbit anti-γHV68 v-cyclin at 1 2000 (kind gifts of Dr. Herbert Virgin), and monoclonal antibody to mouse β-actin at 1 1000 (Sigma Chemical, St. Louis, MO). Blots were washed for 45 minutes in PBS with 0.05% Tween-20, then incubated with donkey anti-mouse or donkey anti-rabbit antibodies at 1 6000 for one hour. Blots were then washed in PBS containing 0.1% Tween-20 for 45 minutes. Proteins were visualized using an ECL Plus Western blotting detection kit (Amersham Pharmacia Biotech).RNA Isolation and RT-PCR Amplification Total RNA was extracted from S11 cells, infected NIH 3T3 cells, infected MB114 cells, and murine lung cell fractions using mirVANA™ miRNA Isolation kit (Ambion, Austin, TX), per manufacturer's instructions. Amplifications were conducted using the following primer sets: γHV68 polIII-1 forward 5′ CAA CAG GTC ACC GAT CC 3′, γHV68 polIII-1 reverse 5′ GGA AGT ACG GCC ATT TC 3′, γHV68 M2 forward 5′ TAA GGA CCT CGT AGA GAT TGG C 3′, γHV68 M2 reverse 5′ ACG TTA AAG TCC CCA TGG AAG C 3′, γHV68 v-cyclin forward 5′ ATT AGC ACT GGG CGT TTC ATG 3′, γHV68 v-cyclin reverse 5′ GAC CTC CGT CAG GAT AAC AAC 3′, mouse β-actin forward 5′ GCC ACC AGT TCG CCA TGG 3′, mouse β-actin reverse 5′ CAA TGC CAT GTT CAA TGG GGT A 3′, mouse 18S forward 5′ AGA TCA AAA CCA ACC CGG TGA 3′, mouse 18S reverse 5′ GGT AAG AGC ATC GAG GGG GC 3′, mouse cyclophilin A forward 5′ ATT TGG CTA TAA GGG TTC CTC 3′, mouse cyclophilin A reverse 5′ ACG CTC CAT GGC TTC CAC AAT 3′, mouse CD31 forward 5′ AGG GGA CCA GCT GCA CAT TAG G 3′ and mouse CD31 reverse 5′ AGG CCG CTT CTC TTG ACC ACT T 3′. RT-PCR reactions were carried out using the OneStep RT-PCR Kit (Qiagen, Valencia, CA) containing a final concentration of primer at 0.5 µM. 100 ng of RNA was treated with RQ1 RNase-Free DNase (Promega, Madison, WI) prior to addition of the RT-PCR reaction mix. RT-PCR reactions were performed as follows: 30 min at 50°C (reverse transcription); 15 min at 95°C (heat inactivation of reverse transcriptase and activation of Taq polymerase); 35–40 amplification cycles of 30 sec at 95°C followed by 30 seconds of 48°C–50°C (dependent on the Tm of the primer set) followed by one min at 72°C and a single incubation for 10 minutes at 72°C. No template and no RT controls were included for each PCR and were negative. Transmission electron microscopy Cells were pelleted (five minutes, 208×g), resuspended in 1 mL PBS, and pelleted again (five minutes, 208×g). Supernatant was removed and 2.5% glutaraldahyde solution (adjusted to pH 7.4 using HCl and to 400 mOsm using CaCl2) added. Samples were processed and imaged by Dr. Gary Mierau, The Children's Hospital Department of Pathology/Laboratory Services, Aurora, CO. Briefly, samples were post-fixed in 2% cacodylate buffered osmium tetroxide (pH 7.4), dehydrated in a graded series of alcohols, and embedded in epoxy resin. Sections, approximately 80 nm in thickness, were stained with uranyl acetate and lead citrate prior to examination at 60 kV with a Zeiss EM-10 transmission electron microscope (Carl Zeiss Inc, Thornwood, NY). Enrichment of lung endothelial cells from infected mice Lung tissues were removed from CD8-alpha knock-out mice six days post-intranasal inoculation of 1×106 PFU γHV68. Tissues were enzymatically digested and endothelial cells purified using the endothelial cell marker CD31 (PECAM-1) (Fig. S4A). Briefly, cells were stained with the following antibodies: anti-CD31-biotin (PECAM-1, clone MEC 13.3, rat IgG2a κ) (BD Bioscience), anti-CD45-PE (B220, clone RA3-6B2, Rat IgG2a κ) (BD Bioscience), anti-F4/80-PE (clone BM8, Rat IgG2a κ) (eBioscience, San Diego, CA), anti-CD4-PE (L3T4, clone RM4-5, Rat IgG2a κ) (eBioscience), anti-CD8a-PE (Ly-2, clone 53-6.7, Rat IgG2a κ) (BD Bioscience), and anti-Ly-6G and Ly-6c-PE (Gr-1, clone RB6-8C5, Rat IgG2b κ) (BD Bioscience). Cells were magnetically labeled with Anti-Biotin MultiSort beads, separated with OctoMACS separation unit, and released from the MultiSort beads as per manufacturer's instructions (Miltenyi Biotec Inc., Auburn, CA). Released cells were incubated with Anti-PE MultiSort beads and depleted of contaminating PE positive cells by magnetic separation. Flow cytometric analysis was performed to confirm flow through fraction from PE column as enriched in CD31 positive cells and depleted of PE positive cells (Fig. S5B). Limiting dilution nested PCR detection of γHV68 genome-positive cells The frequency of lung cells from CD8-alpha knock-out mice containing γHV68 genome was determined using a previously described nested PCR assay (LD-PCR) with single-copy sensitivity to detect gene 50 of γHV68 [77]. Briefly, freshly isolated cells were counted, resupsended in isotonic solution, and then diluted in 104 uninfected NIH 3T12 cells prior to serial dilution plating. Plated cells were lysed overnight in proteinase K, followed by two rounds of nested PCR. Reactions were performed on 12 replicates per dilution per sample and products resolved on a 2% agarose gel and identified by ethidium bromide staining. PCR sensitivity was quantitated using 10, 1, or 0.5 copies of a gene 50 containing plasmid (pBamH I N) diluted in 104 uninfected NIH 3T12 cells. Statistical analysis Data were analyzed using GraphPad Prism software (GraphPad Software, San Diego, CA). Data were analyzed using the paired Student's t test to determine statistical significance. Limiting dilution data were subjected to nonlinear regression analysis, and the frequency of genome-positive cells was calculated using the Poisson distribution to assume that the cell number at which 63.2% of events were detected corresponded to the occurrence of a single event. Accession numbers PECAM-1: NP_001027550; NM_001032378 VCAM-1: NP_03523; NM_011693 Rn18s: NR_003278 γHV68 WUMS complete genome: U97553 γHV68 v-cyclin: AAB66456 γHV68 M2: AAF19270 γHV68 M3: AAF1271; AF127083 γHV68 ORF50: NC_001826.2; NP_04487.1 Text S1 (0.03 MB DOC) Click here for additional data file.(33K, doc) Protocol S1 Isolation and characterization of endothelial cells from murine lung tissue. (0.03 MB DOC) Click here for additional data file.(27K, doc) Figure S1 Schematic of conditions for culturing non-adherent cells following γHV68 infection. Non-adherent cells collected at six days post-infection, MOI = 5PFU/cell were cultured as described in Materials and Methods.(0.04 MB TIF) Click here for additional data file.(41K, tif) Figure S2 RT-PCR analysis of cyclophilin A transcript in infected cells. 100 ng of total RNA from mock infected and infected MB114 and 3T3 cells was added to each RT reaction along with primers specific for the cellular transcript cyclophilin A. No RT and no template controls are indicated. (1.88 MB TIF) Click here for additional data file.(1.7M, tif) Figure S3 Cellular and viral protein expression following γHV68 infection. (A) MB114 cells contained viral proteins as far as 12 days post-infection. Immunoblot of γHV68 v-cyclin protein expression. 20 µg of total protein from mock infected and infected MB114 and 3T3 cells and from S11 cells were loaded per lane and blots probed with antibodies to γHV68 v-cyclin (top) and mouse β-actin (bottom). Mock infected cells were collected at 24 hours. Latent S11 cells do not express lytic viral proteins and served as a negative control. (B) The viral cyclin is not required for surface protein expression changes on infected endothelial cells. MB114 cells harvested at six days post-infection with v-cyclin.STOP γHV68 were analyzed for cell surface expression of Thy1, ICAM-1, and VCAM-1 by flow cytometry. Fluorescence was determined relative to unstained cells (grey). Results are representative from two independent experiments. (2.98 MB TIF) Click here for additional data file.(2.8M, tif) Figure S4 Isolation and characterization of primary murine lung endothelial cells for ex vivo culture. (A) Primary murine lung endothelial cells were isolated for ex vivo studies as described in Protocol S1. (B) Light micrographs of primary lung endothelial cells following isolation (top panel, 40X) and at confluence (bottom panel, 10X). (C) Analysis of cell surface protein expression in 3T3 fibroblast cell lines (negative control, left panel), CD3 lung endothelial cell lines (positive control, middle), and primary lung cells (right panel) by flow cytometry. Endothelial cell specific markers included CD31 and CD54. CD80 and CD86 were included as non-endothelial cell specific markers, though a previous report has identified low level CD80 expression on primary murine lung endothelial cells [71]. Fluorescence was determined relative to unstained cells (grey). Cell morphology and surface expression was similar to previously characterized primary endothelial cells [71]. (0.89 MB TIF) Click here for additional data file.(866K, tif) Figure S5 Isolation and characterization of murine lung endothelial cells infected in vivo. (A) Primary murine lung endothelial cells were isolated for analysis of infection in vivo as described in Materials and Methods. Lung cells were stained for the endothelial cell marker CD31, as well as with a cocktail of PE labeleled antibodies specific to the following cell types (which includes potential contaminating infected cells): macrophages, granulocytes, CD8+ T lymphocytes, CD4+ T lymphocytes, and B lymphocytes. CD31 positive cells were enriched from total lung cells and then finally depleted of cells stained with the PE cocktail. (B) Flow cytometric analysis of lung cell separation following in vivo infection was performed on total lung cells and PE depleted/CD31+ enriched cells. Left and middle panels show representative data (1×106 cells per stain) from an infected mouse (Fig. 8D (0.20 MB TIF) Click here for additional data file.(199K, tif) Acknowledgments We would like to thank Dr. Eric Clambey for his critical reading of the manuscript, Kevin Diebel for his expert advice on RT-PCR analysis, Dr. Gary Mierau for electron microscopy, Calvin Henard for technical assistance, and Dr. Phillip Stevenson and Dr. Skip Virgin for kind gifts of reagents. Footnotes The authors have declared that no competing interests exist. This work was funded by the following agencies: Burroughs Wellcome Fund, National Cancer Institute NIH CA103632, Pre-doctoral Training in Molecular Biology NIH T32-GM08730, Ruth L. Kirschstein National Research Service Award F31 CA132561-01, and The Colorado Center for AIDS Research. References 1. Visser MR, Vercellotti GM, McCarthy JB, Goodman JL, Herbst TJ, et al. Herpes simplex virus inhibits endothelial cell attachment and migration to extracellular matrix proteins. Am J Pathol. 1989;134:223–230. [PubMed] 2. Berk T, Gordon SJ, Choi HY, Cooper HS. Cytomegalovirus infection of the colon: a possible role in exacerbations of inflammatory bowel disease. Am J Gastroenterol. 1985;80:355–360. [PubMed] 3. Speir E, Modali R, Huang ES, Leon MB, Shawl F, et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science. 1994;265:391–394. [PubMed] 4. Chirathaworn C, Pongpanich A, Poovorawan Y. Herpes simplex virus 1 induced LOX-1 expression in an endothelial cell line, ECV 304. Viral Immunol. 2004;17:308–314. [PubMed] 5. Bentz GL, Jarquin-Pardo M, Chan G, Smith MS, Sinzger C, et al. Human cytomegalovirus (HCMV) infection of endothelial cells promotes naive monocyte extravasation and transfer of productive virus to enhance hematogenous dissemination of HCMV. J Virol. 2006;80:11539–11555. [PubMed] 6. Chi JT, Chang HY, Haraldsen G, Jahnsen FL, Troyanskaya OG, et al. Endothelial cell diversity revealed by global expression profiling. Proc Natl Acad Sci U S A. 2003;100:10623–10628. [PubMed] 7. Jarvis MA, Nelson JA. Human cytomegalovirus tropism for endothelial cells: not all endothelial cells are created equal. J Virol. 2007;81:2095–2101. [PubMed] 8. Alber DG, Powell KL, Vallance P, Goodwin DA, Grahame-Clarke C. Herpesvirus infection accelerates atherosclerosis in the apolipoprotein E-deficient mouse. Circulation. 2000;102:779–785. [PubMed] 9. Blaskovic D, Stancekova M, Svobodova J, Mistrikova J. Isolation of five strains of herpesviruses from two species of free living small rodents. Acta Virol. 1980;24:468. [PubMed] 10. Ehtisham S, Sunil-Chandra NP, Nash AA. Pathogenesis of murine gammaherpesvirus infection in mice deficient in CD4 and CD8 T cells. J Virol. 1993;67:5247–5252. [PubMed] 11. Tibbetts SA, van Dyk LF, Speck SH, Virgin HW. Immune control of the number and reactivation phenotype of cells latently infected with a gammaherpesvirus. J Virol. 2002;76:7125–7132. [PubMed] 12. Speck SH, Virgin HW. Host and viral genetics of chronic infection: a mouse model of gamma-herpesvirus pathogenesis. Curr Opin Microbiol. 1999;2:403–409. [PubMed] 13. Simas JP, Efstathiou S. Murine gammaherpesvirus 68: a model for the study of gammaherpesvirus pathogenesis. Trends in Microbiol. 1998;6:276–282. 14. Doherty PC, Christensen JP, Belz GT, Stevenson PG, Sangster MY. Dissecting the host response to a gamm-herpesvirus. Philos Trans R Soc Lond B Biol Sci. 2001;356:581–593. [PubMed] 15. Nash AA, Dutia BM, Stewart JP, Davison AJ. Natural history of murine gamma-herpesvirus infection. Philos Trans R Soc Lond B Biol Sci. 2001;356:569–579. [PubMed] 16. Stewart JP. Of mice and men: murine gammaherpesvirus 68 as a model. Epstein-Barr Virus Rep. 1999;6:31–35. 17. Stewart JP, Usherwood EJ, Ross A, Dyson H, Nash T. Lung epithelial cells are a major site of murine gammaherpesvirus persistence. J Exp Med. 1998;187:1941–1951. [PubMed] 18. van Dyk LF, Virgin HW, Speck SH. The murine gammaherpesvirus 68 v-cyclin is a critical regulator of reactivation from latency. J Virol. 2000;74:7451–7461. [PubMed] 19. Stewart JP, Janjua NJ, Pepper SD, Bennion G, Mackett M, et al. Identification and characterization of murine gammaherpesvirus 68 gp150: a virion membrane glycoprotein. J Virol. 1996;70:3528–3535. [PubMed] 20. Usherwood EJ, Stewart JP, Nash AA. Characterization of tumor cell lines derived from murine gammaherpesvirus-68 infected mice. J Virol. 1996;70:6516–6518. [PubMed] 21. Bowden RJ, Simas JP, Davis AJ, Efstathiou S. Murine gammaherpesvirus 68 encodes tRNA-like sequences which are expressed during latency. J Gen Virol. 1997;78 (Pt 7):1675–1687. [PubMed] 22. Husain SM, Usherwood EJ, Dyson H, Coleclough C, Coppola MA, et al. Murine gammaherpesvirus M2 gene is latency-associated and its protein a target for CD8(+) T lymphocytes. Proc Natl Acad Sci U S A. 1999;96:7508–7513. [PubMed] 23. Radonic A, Thulke S, Bae HG, Muller MA, Siegert W, et al. Reference gene selection for quantitative real-time PCR analysis in virus infected cells: SARS corona virus, Yellow fever virus, Human Herpesvirus-6, Camelpox virus and Cytomegalovirus infections. Virol J. 2005;2:7. [PubMed] 24. Smiley JR. Herpes simplex virus virion host shutoff protein: immune evasion mediated by a viral RNase? J Virol. 2004;78:1063–1068. [PubMed] 25. Glaunsinger B, Ganem D. Highly selective escape from KSHV-mediated host mRNA shutoff and its implications for viral pathogenesis. J Exp Med. 2004;200:391–398. [PubMed] 26. Rowe M, Glaunsinger B, van Leeuwen D, Zuo J, Sweetman D, et al. Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. Proc Natl Acad Sci U S A. 2007;104:3366–3371. [PubMed] 27. Child SJ, Hakki M, De Niro KL, Geballe AP. Evasion of cellular antiviral responses by human cytomegalovirus TRS1 and IRS1. J Virol. 2004;78:197–205. [PubMed] 28. Strom T, Frenkel N. Effects of herpes simplex virus on mRNA stability. J Virol. 1987;61:2198–2207. [PubMed] 29. Adler H, Messerle M, Wagner M, Koszinowski UH. Cloning and mutagenesis of the murine gammaherpesvirus 68 genome as an infectious bacterial artificial chromosome. J Virol. 2000;74:6964–6974. [PubMed] 30. Wetzel A, Chavakis T, Preissner KT, Sticherling M, Haustein UF, et al. Human Thy-1 (CD90) on activated endothelial cells is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Immunol. 2004;172:3850–3859. [PubMed] 31. Haeryfar SM, Hoskin DW. Thy-1: more than a mouse pan-T cell marker. J Immunol. 2004;173:3581–3588. [PubMed] 32. Rege TA, Hagood JS. Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis. FASEB J. 2006;20:1045–1054. [PubMed] 33. Aird WC. Phenotypic heterogeneity of the endothelium: II. Representative vascular beds. Circ Res. 2007;100:174–190. [PubMed] 34. Minami T, Aird WC. Endothelial cell gene regulation. Trends Cardiovasc Med. 2005;15:174–184. [PubMed] 35. Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res. 2007;100:158–173. [PubMed] 36. Fish KN, Soderberg-Naucler SG, Mills LK, Stenglein S, Nelson JA. Human cytomegalovirus persistently infects aortic endothelial cells. J Virol. 1998;72:5661–5668. [PubMed] 37. Fish KN, Stenglein S, Ibanez C, Nelson JA. Cytomegalovirus persistence in macrophages and endothelial cells. Scan J Infect Dis Suppl. 1995;99:34–40. 38. Jarvis MA, Nelson JA. Human cytomegalovirus persistence and latency in endothelial cells and macrophages. Curr Opin Microbiol. 2002;5:403–407. [PubMed] 39. Myerson D, Hackman RC, Nelson JA, Ward DC, McDougall JK. Widespread presence of histologically occult cytomegalovirus. Hum Pathol. 1984;15:430–439. [PubMed] 40. Sinzger C, Grefte A, Plachter B, Gouw AS, The TH, et al. Fibroblasts, epithelial cells, endothelial cells and smooth muscle cells are major targets of human cytomegalovirus infection in lung and gastrointestinal tissues. J Gen Virol. 1995;76 (Pt 4):741–750. [PubMed] 41. Wu W, Vieira J, Fiore N, Banerjee P, Sieburg M, et al. KSHV/HHV-8 infection of human hematopoietic progenitor (CD34+) cells: persistence of infection during hematopoiesis in vitro and in vivo. Blood. 2006;108:141–151. [PubMed] 42. Della BS, Taddeo A, Calabro ML, Brambilla L, Bellinvia M, et al. Peripheral Blood Endothelial Progenitors as Potential Reservoirs of Kaposi's Sarcoma-Associated Herpesvirus. PLoS ONE. 2008;3:e1520. doi:10.1371/journal.pone.0001520. [PubMed] 43. Flore O, Rafii S, Ely S, O'Leary JJ, Hyjek EM, et al. Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus. Nature. 1998;394:588–592. [PubMed] 44. Carroll PA, Brazeau E, Lagunoff M. Kaposi's sarcoma-associated herpesvirus infection of blood endothelial cells induces lymphatic differentiation. Virology. 2004;328:7–18. [PubMed] 45. Hong YK, Foreman K, Shin JW, Hirakawa S, Curry CL, et al. Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet. 2004;36:683–685. [PubMed] 46. Wang HW, Trotter MW, Lagos D, Bourboulia D, Henderson S, et al. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet. 2004;36:687–693. [PubMed] 47. Boshoff C, Schulz TF, Kennedy MM, Graham AK, Fisher C, et al. Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat Med. 1995;1:1274–1278. [PubMed] 48. Staskus KA, Sun R, Miller G, Racz P, Jaslowski A, et al. Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. J Virol. 1999;73:4181–4187. [PubMed] 49. Moses AV, Fish KN, Ruhl R, Smith PP, Strussenberg JG, et al. Long-term infection and transformation of dermal microvascular endothelial cells by human herpesvirus 8. J Virol. 1999;73:6892–6902. [PubMed] 50. Lagunoff M, Bechtel J, Venetsanakos E, Roy AM, Abbey N, et al. De novo infection and serial transmission of Kaposi's sarcoma-associated herpesvirus in cultured endothelial cells. J Virol. 2002;76:2440–2448. [PubMed] 51. Ciufo DM, Cannon JS, Poole LJ, Wu FY, Murray P, et al. Spindle cell conversion by Kaposi's sarcoma-associated herpesvirus: formation of colonies and plaques with mixed lytic and latent gene expression in infected primary dermal microvascular endothelial cell cultures. J Virol. 2001;75:5614–5626. [PubMed] 52. Mutlu AD, Cavallin LE, Vincent L, Chiozzini C, Eroles P, et al. In Vivo-Restricted and Reversible Malignancy Induced by Human Herpesvirus-8 KSHV: A Cell and Animal Model of Virally Induced Kaposi's Sarcoma. Cancer Cell. 2007;11:245–258. [PubMed] 53. van Dyk LF, Hess JL, Katz JD, Jacoby M, Speck SH, et al. The murine gammaherpesvirus 68 v-cyclin gene is an oncogene that promotes cell cycle progression in primary lymphocytes. J Virol. 1999;73:5110–5122. [PubMed] 54. Song MJ, Hwang S, Wong WH, Wu TT, Lee S, et al. Identification of viral genes essential for replication of murine gamma-herpesvirus 68 using signature-tagged mutagenesis. Proc Natl Acad Sci U S A. 2005;102:3805–3810. [PubMed] 55. Upton JW, Speck SH. Evidence for CDK-dependent and CDK-independent functions of the murine gammaherpesvirus 68 v-cyclin. J Virol. 2006;80:11946–11959. [PubMed] 56. Cheng EH, Nicholas J, Bellows DS, Hayward GS, Guo HG, et al. A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak. Proc Natl Acad Sci U S A. 1997;94:690–694. [PubMed] 57. Montaner S, Sodhi A, Pece S, Mesri EA, Gutkind JS. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B. Cancer Res. 2001;61:2641–2648. [PubMed] 58. Sodhi A, Chaisuparat R, Hu J, Ramsdell AK, Manning BD, et al. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell. 2006;10:133–143. [PubMed] 59. Montaner S, Sodhi A, Molinolo A, Bugge TH, Sawai ET, et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell. 2003;3:23–36. [PubMed] 60. Lembo D, Donalisio M, Hofer A, Cornaglia M, Brune W, et al. The ribonucleotide reductase R1 homolog of murine cytomegalovirus is not a functional enzyme subunit but is required for pathogenesis. J Virol. 2004;78:4278–4288. [PubMed] 61. Tomescu C, Law WK, Kedes DH. Surface downregulation of major histocompatibility complex class I, PE-CAM, and ICAM-1 following de novo infection of endothelial cells with Kaposi's sarcoma-associated herpesvirus. J Virol. 2003;77:9669–9684. [PubMed] 62. Adang LA, Tomescu C, Law WK, Kedes DH. Intracellular Kaposi's sarcoma-associated herpesvirus load determines early loss of immune synapse components. J Virol. 2007;81:5079–5090. [PubMed] 63. Mansouri M, Douglas J, Rose PP, Gouveia K, Thomas G, et al. Kaposi sarcoma herpesvirus K5 removes CD31/PECAM from endothelial cells. Blood. 2006;108:1932–1940. [PubMed] 64. Bartee E, McCormack A, Fruh K. Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog. 2006;2:e107. doi:10.1371/journal.ppat.0020107. [PubMed] 65. Lorenzo ME, Jung JU, Ploegh HL. Kaposi's sarcoma-associated herpesvirus K3 utilizes the ubiquitin-proteasome system in routing class major histocompatibility complexes to late endocytic compartments. J Virol. 2002;76:5522–5531. [PubMed] 66. Hewitt EW, Duncan L, Mufti D, Baker J, Stevenson PG, et al. Ubiquitylation of MHC class I by the K3 viral protein signals internalization and TSG101-dependent degradation. EMBO J. 2002;21:2418–2429. [PubMed] 67. Mages J, Freimuller K, Lang R, Hatzopoulos AK, Guggemoos S, et al. Proteins of the Secretory Pathway Govern Virus Productivity During Lytic Gammaherpesvirus Infection. J Cell Mol Med. 2008 68. Moore SA, Prokuski LJ, Figard PH, Spector AA, Hart MN. Murine cerebral microvascular endothelium incorporate and metabolize 12-hydroxyeicosatetraenoic acid. J Cell Physiol. 1988;137:75–85. [PubMed] 69. Chopra H, Fligiel SE, Hatfield JS, Nelson KK, Diglio CA, et al. An in vivo study of the role of the tumor cell cytoskeleton in tumor cell-platelet-endothelial cell interactions. Cancer Res. 1990;50:7686–7696. [PubMed] 70. Weck KE, Barkon ML, Yoo LI, Speck SH, Virgin HW, IV Mature B cells are required for acute splenic infection, but not for establishment of latency, by murine gammaherpesvirus 68. J Virol. 1996;70:6775–6780. [PubMed] 71. Marelli-Berg FM, Peek E, Lidington EA, Stauss HJ, Lechler RI. Isolation of endothelial cells from murine tissue. J Immunol Methods. 2000;244:205–215. [PubMed] 72. Virgin HW, Latreille P, Wamsley P, Hallsworth K, Weck KE, et al. Complete sequence and genomic analysis of murine gammaherpesvirus 68. J Virol. 1997;71:5894–5904. [PubMed] 73. Stevenson PG, May JS, Smith XG, Marques S, Adler H, et al. K3-mediated evasion of CD8(+) T cells aids amplification of a latent gamma-herpesvirus. Nat Immunol. 2002;3:733–740. [PubMed] 74. Unkeless JC. Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J Exp Med. 1979;150:580–596. [PubMed] 75. de Lima BD, May JS, Stevenson PG. Murine gammaherpesvirus 68 lacking gp150 shows defective virion release but establishes normal latency in vivo. J Virol. 2004;78:5103–5112. [PubMed] 76. Lopes FB, Colaco S, May JS, Stevenson PG. Characterization of murine gammaherpesvirus 68 glycoprotein B. J Virol. 2004;78:13370–13375. [PubMed] 77. van Dyk LF, Virgin HW, Speck SH. Maintenance of gammaherpesvirus latency requires viral cyclin in the absence of B lymphocytes. J Virol. 2003;77:5118–5126. [PubMed] 78. Ewing P, Wilke A, Brockhoff G, Andreesen R, Eissner G, et al. Isolation and transplantation of allogeneic pulmonary endothelium derived from GFP transgenic mice. J Immunol Methods. 2003;283:307–315. [PubMed] 79. Freeman GJ, Freedman AS, Segil JM, Lee G, Whitman JF, et al. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol. 1989;143:2714–2722. [PubMed] 80. Larsen CP, Ritchie SC, Hendrix R, Linsley PS, Hathcock KS, et al. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J Immunol. 1994;152:5208–5219. [PubMed] 81. Rattis FM, Peguet-Navarro J, Staquet MJ, Dezutter-Dambuyant C, Courtellemont P, et al. Expression and function of B7-1 (CD80) and B7-2 (CD86) on human epidermal Langerhans cells. Eur J Immunol. 1996;26:449–453. [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||
Am J Pathol. 1989 Jan; 134(1):223-30.
[Am J Pathol. 1989]Viral Immunol. 2004; 17(2):308-14.
[Viral Immunol. 2004]J Virol. 2006 Dec; 80(23):11539-55.
[J Virol. 2006]Proc Natl Acad Sci U S A. 2003 Sep 16; 100(19):10623-8.
[Proc Natl Acad Sci U S A. 2003]J Virol. 2007 Mar; 81(5):2095-101.
[J Virol. 2007]Acta Virol. 1980 Dec; 24(6):468.
[Acta Virol. 1980]Curr Opin Microbiol. 1999 Aug; 2(4):403-9.
[Curr Opin Microbiol. 1999]J Exp Med. 1998 Jun 15; 187(12):1941-51.
[J Exp Med. 1998]Proc Natl Acad Sci U S A. 2003 Sep 16; 100(19):10623-8.
[Proc Natl Acad Sci U S A. 2003]J Virol. 2000 Aug; 74(16):7451-61.
[J Virol. 2000]J Virol. 1996 Jun; 70(6):3528-35.
[J Virol. 1996]J Virol. 1996 Sep; 70(9):6516-8.
[J Virol. 1996]J Gen Virol. 1997 Jul; 78 ( Pt 7)():1675-87.
[J Gen Virol. 1997]Proc Natl Acad Sci U S A. 1999 Jun 22; 96(13):7508-13.
[Proc Natl Acad Sci U S A. 1999]Virol J. 2005 Feb 10; 2():7.
[Virol J. 2005]J Virol. 2004 Feb; 78(3):1063-8.
[J Virol. 2004]J Virol. 1987 Jul; 61(7):2198-207.
[J Virol. 1987]J Virol. 2000 Aug; 74(15):6964-74.
[J Virol. 2000]J Immunol. 2004 Mar 15; 172(6):3850-9.
[J Immunol. 2004]FASEB J. 2006 Jun; 20(8):1045-54.
[FASEB J. 2006]J Virol. 2000 Aug; 74(16):7451-61.
[J Virol. 2000]J Virol. 2000 Aug; 74(16):7451-61.
[J Virol. 2000]Am J Pathol. 1989 Jan; 134(1):223-30.
[Am J Pathol. 1989]Viral Immunol. 2004; 17(2):308-14.
[Viral Immunol. 2004]Circ Res. 2007 Feb 2; 100(2):174-90.
[Circ Res. 2007]Circ Res. 2007 Feb 2; 100(2):158-73.
[Circ Res. 2007]J Virol. 1998 Jul; 72(7):5661-8.
[J Virol. 1998]J Gen Virol. 1995 Apr; 76 ( Pt 4)():741-50.
[J Gen Virol. 1995]Blood. 2006 Jul 1; 108(1):141-51.
[Blood. 2006]PLoS One. 2008 Jan 30; 3(1):e1520.
[PLoS One. 2008]Curr Opin Microbiol. 1999 Aug; 2(4):403-9.
[Curr Opin Microbiol. 1999]Nature. 1998 Aug 6; 394(6693):588-92.
[Nature. 1998]Nat Genet. 2004 Jul; 36(7):687-93.
[Nat Genet. 2004]Nat Med. 1995 Dec; 1(12):1274-8.
[Nat Med. 1995]J Virol. 1999 May; 73(5):4181-7.
[J Virol. 1999]Blood. 2006 Jul 1; 108(1):141-51.
[Blood. 2006]J Virol. 2000 Aug; 74(16):7451-61.
[J Virol. 2000]J Virol. 1999 Jun; 73(6):5110-22.
[J Virol. 1999]Proc Natl Acad Sci U S A. 2005 Mar 8; 102(10):3805-10.
[Proc Natl Acad Sci U S A. 2005]J Virol. 2006 Dec; 80(24):11946-59.
[J Virol. 2006]Proc Natl Acad Sci U S A. 1997 Jan 21; 94(2):690-4.
[Proc Natl Acad Sci U S A. 1997]Cancer Cell. 2003 Jan; 3(1):23-36.
[Cancer Cell. 2003]J Virol. 2004 Apr; 78(8):4278-88.
[J Virol. 2004]J Virol. 2003 Sep; 77(17):9669-84.
[J Virol. 2003]EMBO J. 2002 May 15; 21(10):2418-29.
[EMBO J. 2002]J Cell Physiol. 1988 Oct; 137(1):75-85.
[J Cell Physiol. 1988]Cancer Res. 1990 Dec 1; 50(23):7686-96.
[Cancer Res. 1990]J Virol. 1996 Sep; 70(9):6516-8.
[J Virol. 1996]Proc Natl Acad Sci U S A. 1999 Jun 22; 96(13):7508-13.
[Proc Natl Acad Sci U S A. 1999]J Virol. 1996 Oct; 70(10):6775-80.
[J Virol. 1996]J Virol. 1997 Aug; 71(8):5894-904.
[J Virol. 1997]Nat Immunol. 2002 Aug; 3(8):733-40.
[Nat Immunol. 2002]J Virol. 2000 Aug; 74(16):7451-61.
[J Virol. 2000]J Exp Med. 1979 Sep 19; 150(3):580-96.
[J Exp Med. 1979]J Virol. 2004 May; 78(10):5103-12.
[J Virol. 2004]J Virol. 2004 Dec; 78(23):13370-5.
[J Virol. 2004]J Virol. 2003 May; 77(9):5118-26.
[J Virol. 2003]J Immunol Methods. 2000 Oct 20; 244(1-2):205-15.
[J Immunol Methods. 2000]